At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform called HERMES, delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology.
Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.
Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021.
Company Details
- Employees
- 23
- Founded
- -
- Address
- 29, Rue Du Faubourg Saint-Jacques, Paris,île-De-France 75014,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Gene therapy, peripheral nervous system disorders, neurogenic bladder, HSV-1 vector platform, urinary bladder dysfunction, Herpes type 1 gene therapy platform, treatment of nervous system disorders.
- HQ
- Paris, Île-de-France
Eg 427 Questions
Eg 427's LinkedIn profile is https://fr.linkedin.com/company/eg427
Eg 427 has
23 employees.
View email and phone details for 23
employees at Eg 427.
Eg 427's industry is
Biotechnology Research
Eg 427's top competitors are
Mnemo Therapeutics,
Egle Therapeutics,
73 Strings,
Wavo,
Spore.bio,
Dametis,
Ochy,
Cycloid,
Circle Safe,
Genial.
Eg 427's categories are Biotechnology Research
Eg 427's founding year is 2019
